Detected ·
Xeltis
€20.5M—
Xeltis raises an additional €20.5M in funding to advance aXess™ toward FDA approval and US commercial launch. The round was led by Horizon 3 Healthcare, with continued support from EIC, Invest-NL, Vi Partners, EQT Life Sciences, and DaVita.
- Website
- www.xeltis.com
- linkedin.com/company/xeltis
- Amount
- €20 500 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-31 16:04:50 UTC
- Signal ID
- 13bc6f2c-434e-4a2a-aadd-e72c93dd05ed
As the API returns it
{
"id": "13bc6f2c-434e-4a2a-aadd-e72c93dd05ed",
"created_at": "2026-07-31T16:04:50.435924Z",
"company_name": "Xeltis",
"company_website_url": "www.xeltis.com",
"company_linkedin_url": "https://www.linkedin.com/company/xeltis",
"event_type": "funding",
"funding_amount": 20500000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Xeltis raises an additional €20.5M in funding to advance aXess™ toward FDA approval and US commercial launch. The round was led by Horizon 3 Healthcare, with continued support from EIC, Invest-NL, Vi Partners, EQT Life Sciences, and DaVita.*"
}